NORTHERN TRUST CORP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$49,422,888
-16.7%
948,798
+1.2%
0.01%
-9.1%
Q2 2023$59,361,740
+19.5%
937,488
+2.2%
0.01%
+10.0%
Q1 2023$49,681,434
+0.5%
917,478
-1.7%
0.01%0.0%
Q4 2022$49,414,632
+14.0%
933,761
+0.3%
0.01%0.0%
Q3 2022$43,331,000
-18.9%
931,263
-0.5%
0.01%
-9.1%
Q2 2022$53,402,000
-0.1%
935,572
+7.0%
0.01%
+22.2%
Q1 2022$53,479,000
+25.7%
873,978
+7.6%
0.01%
+28.6%
Q4 2021$42,531,000
+37.7%
812,586
-2.0%
0.01%
+40.0%
Q3 2021$30,897,000
-11.7%
828,797
-3.4%
0.01%
-16.7%
Q2 2021$35,010,000
+25.1%
857,660
+4.0%
0.01%
+20.0%
Q1 2021$27,984,000
-7.8%
824,748
-13.6%
0.01%
-16.7%
Q4 2020$30,354,000
+21.9%
954,551
-1.7%
0.01%
+20.0%
Q3 2020$24,906,000
+9.4%
970,615
+9.5%
0.01%0.0%
Q2 2020$22,757,000
+118.6%
886,518
+30.9%
0.01%
+66.7%
Q1 2020$10,411,000
-46.8%
677,473
+18.8%
0.00%
-25.0%
Q4 2019$19,568,000
+345.4%
570,348
-3.0%
0.00%
+300.0%
Q3 2019$4,393,000
-39.6%
588,177
+4.9%
0.00%
-50.0%
Q2 2019$7,277,000
+8.2%
560,601
+1.6%
0.00%0.0%
Q1 2019$6,725,000
+7.7%
552,037
+0.6%
0.00%0.0%
Q4 2018$6,247,000
-48.0%
548,507
-1.0%
0.00%
-33.3%
Q3 2018$12,019,000
+26.0%
553,879
+2.6%
0.00%
+50.0%
Q2 2018$9,542,000
-8.2%
540,016
+9.4%
0.00%
-33.3%
Q1 2018$10,390,000
+47.6%
493,563
+1.6%
0.00%
+50.0%
Q4 2017$7,038,000
+10.5%
485,965
+20.3%
0.00%0.0%
Q3 2017$6,372,000
+30.4%
403,825
+2.7%
0.00%
+100.0%
Q2 2017$4,886,000
-27.2%
393,385
-4.7%
0.00%
-50.0%
Q1 2017$6,710,000
+9.3%
412,864
+1.5%
0.00%0.0%
Q4 2016$6,137,000
+2.0%
406,619
+3.0%
0.00%0.0%
Q3 2016$6,014,000
-60.5%
394,617
+0.5%
0.00%
-60.0%
Q2 2016$15,236,000
+68.9%
392,471
+22.6%
0.01%
+66.7%
Q1 2016$9,019,000
-47.0%
320,115
+1.2%
0.00%
-50.0%
Q4 2015$17,022,000
+69.0%
316,448
+25.8%
0.01%
+100.0%
Q3 2015$10,071,000
+34.9%
251,537
+7.7%
0.00%
+50.0%
Q2 2015$7,463,000
+51.6%
233,588
+13.3%
0.00%
+100.0%
Q1 2015$4,922,000
+55.7%
206,149
+15.1%
0.00%0.0%
Q4 2014$3,162,000
+24.6%
179,147
-3.2%
0.00%0.0%
Q3 2014$2,537,000
+241.5%
185,043
+319.6%
0.00%
Q2 2014$743,000
+98.1%
44,099
+114.0%
0.00%
Q1 2014$375,00020,6080.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders